Amber Salzman Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Amber Salzman.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Amber Salzman. Amber Salzman is a President and CEO in Adverum Biotechnologies, Inc. ($AAVL) and a President and COO in Adverum Biotechnologies, Inc. ($AAVL) and a Director in AKCEA THERAPEUTICS, INC. ($AKCA).
Address: C/O AVALANCHE BIOTECHNOLOGIES, INC. 1035 O'BRIEN DRIVE MENLO PARK 94025 CA
Companies in which Amber Salzman is an Insider
Adverum Biotechnologies, Inc.
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of Amber Salzman: President and CEO, President and COO
Holdings: 891,766 shares
Latest Transaction: Feb 20 2018
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
AKCEA THERAPEUTICS, INC.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Amber Salzman: Director
Holdings: 0 shares
Latest Transaction: Oct 13 2020
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Latest Insider Trading Transactions of Amber Salzman
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | Salzman Amber | Director | Option Exercise | D | 16.14 | 26,400 | 426,096 | 0 | |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | Salzman Amber | Director | Option Exercise | D | 17.94 | 53,000 | 950,820 | 0 | |
| Apr 15 2020 | AKCA | AKCEA THERAPEUTICS ... | Salzman Amber | Director | Option Exercise | A | 16.14 | 26,400 | 426,096 | 26,400 | |
| Feb 13 2020 | AKCA | AKCEA THERAPEUTICS ... | Salzman Amber | Director | Option Exercise | A | 17.94 | 53,000 | 950,820 | 53,000 | |
| Feb 20 2018 | ADVM | Adverum Biotechnol ... | Salzman Amber | President and CEO | Option Exercise | A | 6.40 | 478,000 | 3,059,200 | 478,000 | |
| Feb 13 2017 | AAVL | Adverum Biotechnol ... | Salzman Amber | President and CEO | Option Exercise | A | 2.70 | 378,000 | 1,020,600 | 378,000 | |
| Feb 13 2017 | AAVL | Adverum Biotechnol ... | Salzman Amber | President and CEO | Grant | A | 0.00 | 262,000 | 0 | 891,766 | 629.8 K to 891.8 K (+41.60 %) |